FDA Approves GLP-1 pill, Foundayo, for Weight Loss

Translate to Spanish or other 102 languages!

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes
The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes
- Advertisement -

Medical News Today

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems.

This approval makes Eli Lilly’s oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug available in pill form, after Wegovy, which gained approval in December 2025.

- Advertisement -

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/fda-approves-oral-glp-1-pill-foundayo-for-weight-loss

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

How a New Diagnostic Marker is Changing Prostate Cancer Detection

Aggressive prostate cancers often lose expression of traditional markers after treatment, making it hard to diagnose the tumor’s origin and complicating treatment decisions

Creatine Surges in Popularity as Steroid Use Declines

U.S. teens report far less anabolic steroid use than they did two decades ago, but creatine use has risen rapidly in recent years, according to a new University of Michigan study.

The Verdict on the Perfect Bedroom Temperature

Mega Doctor News CLEVELAND CLINIC - Do you like your bedroom hot or...

STHS to Host Webinar on Importance of Healthy Aging, May 19th

Mega Doctor News Healthy aging is about more than adding years to...
- Advertisement -